<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003925</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067112</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-D-1641</secondary_id>
    <secondary_id>WSU-04-28-98-M02-FB</secondary_id>
    <secondary_id>NCI-G99-1526</secondary_id>
    <nct_id>NCT00003925</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy In Treating Patients With Advanced Cancer</brief_title>
  <official_title>Phase I Study of Gemcitabine (Gemzar) and UFT/Leucovorin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining gemcitabine,&#xD;
      fluorouracil-uracil and leucovorin in treating patients who have advanced cancer that has not&#xD;
      responded to previous therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated doses of gemcitabine, fluorouracil-uracil (UFT), and&#xD;
           leucovorin calcium in patients with advanced refractory cancer.&#xD;
&#xD;
        -  Assess the toxicity of this combination regimen in this patient population.&#xD;
&#xD;
        -  Evaluate this regimen in terms of response rate, response duration, and overall survival&#xD;
           in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of gemcitabine and fluorouracil-uracil.&#xD;
&#xD;
      Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15. Patients receive oral&#xD;
      leucovorin calcium immediately followed by oral fluorouracil-uracil (UFT) three times a day&#xD;
      on days 1-21. Courses are repeated every 28 days. Treatment continues in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of gemcitabine and UFT until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 6 patients experience dose limiting toxicities.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1998</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tegafur-uracil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed malignancy refractory to existing&#xD;
             chemotherapy or for which no standard therapy exists&#xD;
&#xD;
          -  Evaluable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  SWOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin greater than 8.0 mg/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  AST less than 3.0 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active infection requiring antibiotics&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior systemic cytotoxic chemotherapy (including fluorouracil)&#xD;
             and recovered&#xD;
&#xD;
          -  No prior gemcitabine&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior hormonal therapy allowed&#xD;
&#xD;
          -  No concurrent hormonal contraception&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy to large areas of active bone marrow and&#xD;
             recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Prior major surgery allowed and recovered&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior or concurrent antiviral nucleosides&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip A. Philip, MD, PhD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>El-Rayes BF, Zalupski M, Shields AF, Manza SG, LoRusso P, Philip PA. A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin. Am J Clin Oncol. 2007 Apr;30(2):101-5. doi: 10.1097/01.coc.0000251223.98193.f4.</citation>
    <PMID>17414457</PMID>
  </results_reference>
  <results_reference>
    <citation>Philip PA, Ibrahim D, Zalupski M, Arlauskas P, Shields A. Gemcitabine and UFT plus oral calcium folinate: phase I study. Oncology (Williston Park). 1999 Jul;13(7 Suppl 3):116-9.</citation>
    <PMID>10442378</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 1, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2003</study_first_posted>
  <last_update_submitted>April 5, 2013</last_update_submitted>
  <last_update_submitted_qc>April 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Tegafur</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

